Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.
Cao J, Brouwer NJ, Richards KE, Marinkovic M, van Duinen S, Hurkmans D, Verdegaal EME, Jordanova ES, Jager MJ. Cao J, et al. Among authors: verdegaal eme. Oncotarget. 2017 May 20;8(33):54722-54734. doi: 10.18632/oncotarget.18039. eCollection 2017 Aug 15. Oncotarget. 2017. PMID: 28903377 Free PMC article.
Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer.
Hurkmans DP, Verdegaal EME, Hogan SA, de Wijn R, Hovestad L, van den Heuvel DMA, Ruijtenbeek R, Welters MJP, van Brakel M, Basak EA, Pinedo HM, Lamers CHJ, van de Werken HJG, Groten JP, Debets R, Levesque MP, Dummer R, Kapiteijn E, Mathijssen RHJ, Aerts JGJV, van der Burg SH. Hurkmans DP, et al. Among authors: verdegaal eme. J Immunother Cancer. 2020 Dec;8(2):e001607. doi: 10.1136/jitc-2020-001607. J Immunother Cancer. 2020. PMID: 33427690 Free PMC article.
Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha.
Verdegaal EM, Visser M, Ramwadhdoebé TH, van der Minne CE, van Steijn JA, Kapiteijn E, Haanen JB, van der Burg SH, Nortier JW, Osanto S. Verdegaal EM, et al. Cancer Immunol Immunother. 2011 Jul;60(7):953-63. doi: 10.1007/s00262-011-1004-8. Epub 2011 Mar 24. Cancer Immunol Immunother. 2011. PMID: 21431917 Free PMC article. Clinical Trial.
Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study.
Verdegaal E, van der Kooij MK, Visser M, van der Minne C, de Bruin L, Meij P, Terwisscha van Scheltinga A, Welters MJ, Santegoets S, de Miranda N, Roozen I, Liefers GJ, Kapiteijn E, van der Burg SH. Verdegaal E, et al. J Immunother Cancer. 2020 Mar;8(1):e000166. doi: 10.1136/jitc-2019-000166. J Immunother Cancer. 2020. PMID: 32238469 Free PMC article. Clinical Trial.
Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial.
van der Kooij MK, Verdegaal EME, Visser M, de Bruin L, van der Minne CE, Meij PM, Roozen ICFM, Jonker MA, van den Bosch S, Liefers GJ, Speetjens FM, van der Burg SH, Kapiteijn E. van der Kooij MK, et al. Among authors: verdegaal eme. BMJ Open. 2020 Nov 24;10(11):e044036. doi: 10.1136/bmjopen-2020-044036. BMJ Open. 2020. PMID: 33234662 Free PMC article.
46 results